Stock code: 6564

Enimmune

2

• Found in 2014

• Capital: NTD 600,000,000

• Major shareholder: Adimmune Corporation, Diamond

BioFund, GAINS Investment Corporation, Mega Bank,

Wen Teng Investment

• Business: vaccines & diagnostics developer/distributor

• Product: EV71 vaccine, EV71+CA16 vaccine, JEV

Vaccine, Pneumococcal Vaccine, COVID-19 antigen

rapid test

• Chairman: Chung-Cheng Liu, Ph.D.

• President: Vic Chang, CIA

Millstone

3

2014 2016 2018

2015 2017 2019

Enimmune Corp. was found

EV71 vaccine phase II study was approved by TFDA

Enimmune stock was public offering

CMO inspection by TDFA was completed

EV71 vaccine phase II study was completed.

Enimmune listed on Taiwan emerging stock market

EV71 vaccine phase III study was approved by MO in Vietnam

A+ Industrial Innovative R&D program, MOEA with NTD 24 MM subsidy

EV71 vaccine phase III study was completed

Compliance with the biotech new drug development regulations as the new drug development company

Tuberculin test, PPD test launched in Taiwan

2020

EV71 vaccine NDA filed to TFDA reviewing

Passed GDP inspection

Development for COVID-19 antigen rapid test

Strategy Development

4

drug discovery

development

animal test pre-

clinical

clinical test phase I, II, III

Market IND NDA

Research Development Marketing

Research Institutions, Bio-Tec. Co Enimmune Business Scope

• EV 71 Vaccine Adimmune

• Japanese Encephalitis Vaccine, JEV

• AdimFlu-S (QIS) (privately funded )

• Tuberculin test, PPD

• Tetanus Toxoid, TTA • EV 71 Vaccine

• Pneumococcal Vaccine

• EV71+CA16 vaccine

• Diagnostics

Adimmune

Abcombi

NHRI

• COVID-19 • EV-71 • FLU